Altimmune Net Income
| ALT Stock | USD 5.55 0.05 0.89% |
As of the 2nd of February, Altimmune shows the Downside Deviation of 5.69, mean deviation of 4.01, and Risk Adjusted Performance of 0.0861. Altimmune technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Altimmune Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 22.2 K | Revenue | Earnings Share (1.18) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -85.6 M | -81.3 M | |
| Net Loss | -85.6 M | -81.3 M | |
| Net Loss | -76.2 M | -72.4 M | |
| Net Loss | (1.20) | (1.27) | |
| Net Income Per E B T | 0.90 | 0.58 |
Altimmune | Net Income | Build AI portfolio with Altimmune Stock |
The evolution of Net Income for Altimmune provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Altimmune compares to historical norms and industry peers.
Latest Altimmune's Net Income Growth Pattern
Below is the plot of the Net Income of Altimmune over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Altimmune financial statement analysis. It represents the amount of money remaining after all of Altimmune operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Altimmune's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Altimmune's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (95.06 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Altimmune Net Income Regression Statistics
| Arithmetic Mean | (30,999,963) | |
| Coefficient Of Variation | (221.49) | |
| Mean Deviation | 45,621,047 | |
| Median | (39,171,152) | |
| Standard Deviation | 68,662,427 | |
| Sample Variance | 4714.5T | |
| Range | 290.9M | |
| R-Value | (0.57) | |
| Mean Square Error | 3367.1T | |
| R-Squared | 0.33 | |
| Significance | 0.02 | |
| Slope | (7,816,317) | |
| Total Sum of Squares | 75432.5T |
Altimmune Net Income History
Other Fundumenentals of Altimmune
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Altimmune Net Income component correlations
Altimmune Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Altimmune is extremely important. It helps to project a fair market value of Altimmune Stock properly, considering its historical fundamentals such as Net Income. Since Altimmune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Altimmune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Altimmune's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Altimmune introduce new products? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Altimmune's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Altimmune represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Altimmune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Altimmune 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Altimmune's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Altimmune.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Altimmune on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Altimmune or generate 0.0% return on investment in Altimmune over 90 days. Altimmune is related to or competes with DBV Technologies, Annexon, Frequency Therapeutics, EnGene Holdings, Larimar Therapeutics, Aura Biosciences, and Amarin PLC. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver dise... More
Altimmune Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Altimmune's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Altimmune upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.69 | |||
| Information Ratio | 0.0994 | |||
| Maximum Drawdown | 33.75 | |||
| Value At Risk | (5.05) | |||
| Potential Upside | 9.8 |
Altimmune Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Altimmune's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Altimmune's standard deviation. In reality, there are many statistical measures that can use Altimmune historical prices to predict the future Altimmune's volatility.| Risk Adjusted Performance | 0.0861 | |||
| Jensen Alpha | 0.5985 | |||
| Total Risk Alpha | 0.3407 | |||
| Sortino Ratio | 0.1046 | |||
| Treynor Ratio | 0.6989 |
Altimmune February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0861 | |||
| Market Risk Adjusted Performance | 0.7089 | |||
| Mean Deviation | 4.01 | |||
| Semi Deviation | 5.09 | |||
| Downside Deviation | 5.69 | |||
| Coefficient Of Variation | 935.71 | |||
| Standard Deviation | 5.99 | |||
| Variance | 35.86 | |||
| Information Ratio | 0.0994 | |||
| Jensen Alpha | 0.5985 | |||
| Total Risk Alpha | 0.3407 | |||
| Sortino Ratio | 0.1046 | |||
| Treynor Ratio | 0.6989 | |||
| Maximum Drawdown | 33.75 | |||
| Value At Risk | (5.05) | |||
| Potential Upside | 9.8 | |||
| Downside Variance | 32.35 | |||
| Semi Variance | 25.91 | |||
| Expected Short fall | (5.02) | |||
| Skewness | (0.53) | |||
| Kurtosis | 4.37 |
Altimmune Backtested Returns
Altimmune appears to be moderately volatile, given 3 months investment horizon. Altimmune secures Sharpe Ratio (or Efficiency) of 0.14, which signifies that the company had a 0.14 % return per unit of risk over the last 3 months. By analyzing Altimmune's technical indicators, you can evaluate if the expected return of 0.85% is justified by implied risk. Please makes use of Altimmune's Risk Adjusted Performance of 0.0861, downside deviation of 5.69, and Mean Deviation of 4.01 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Altimmune holds a performance score of 11. The firm shows a Beta (market volatility) of 0.9, which signifies possible diversification benefits within a given portfolio. Altimmune returns are very sensitive to returns on the market. As the market goes up or down, Altimmune is expected to follow. Please check Altimmune's value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Altimmune's price patterns will revert.
Auto-correlation | 0.76 |
Good predictability
Altimmune has good predictability. Overlapping area represents the amount of predictability between Altimmune time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Altimmune price movement. The serial correlation of 0.76 indicates that around 76.0% of current Altimmune price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.76 | |
| Spearman Rank Test | 0.74 | |
| Residual Average | 0.0 | |
| Price Variance | 0.55 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Altimmune Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Altimmune reported net income of (95.06 Million). This is 127.85% lower than that of the Biotechnology sector and 235.71% lower than that of the Health Care industry. The net income for all United States stocks is 116.65% higher than that of the company.
Altimmune Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Altimmune's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Altimmune could also be used in its relative valuation, which is a method of valuing Altimmune by comparing valuation metrics of similar companies.Altimmune is currently under evaluation in net income category among its peers.
Altimmune Current Valuation Drivers
We derive many important indicators used in calculating different scores of Altimmune from analyzing Altimmune's financial statements. These drivers represent accounts that assess Altimmune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Altimmune's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 378.2M | 771.9M | 599.0M | 511.9M | 460.7M | 483.8M | |
| Enterprise Value | 189.4M | 662.0M | 464.6M | 476.7M | 429.0M | 450.5M |
Altimmune ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Altimmune's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Altimmune's managers, analysts, and investors.Environmental | Governance | Social |
Altimmune Institutional Holders
Institutional Holdings refers to the ownership stake in Altimmune that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Altimmune's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Altimmune's value.| Shares | Bank Of America Corp | 2025-06-30 | 716 K | Northern Trust Corp | 2025-06-30 | 640.3 K | Citadel Advisors Llc | 2025-06-30 | 523.5 K | Goldman Sachs Group Inc | 2025-06-30 | 499.2 K | Group One Trading, Lp | 2025-06-30 | 469.4 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 447.5 K | Two Sigma Investments Llc | 2025-06-30 | 437.3 K | Fmr Inc | 2025-06-30 | 401.8 K | Beirne Wealth Consulting Services, Llc | 2025-06-30 | 342.5 K | Blackrock Inc | 2025-06-30 | 6.4 M | Vanguard Group Inc | 2025-06-30 | 5.2 M |
Fund Asset Allocation for Altimmune
The fund invests 21.57% of asset under management in tradable equity instruments, with the rest of investments concentrated in bonds (15.26%) and various exotic instruments.Asset allocation divides Altimmune's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors for a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will manage securities in the fund's portfolio as market conditions and the fund's objectives change.
Altimmune Fundamentals
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 443.81 M | ||||
| Shares Outstanding | 125.23 M | ||||
| Shares Owned By Insiders | 0.64 % | ||||
| Shares Owned By Institutions | 40.05 % | ||||
| Number Of Shares Shorted | 26.41 M | ||||
| Price To Earning | (1.66) X | ||||
| Price To Book | 3.44 X | ||||
| Price To Sales | 35,065 X | ||||
| Revenue | 20 K | ||||
| Gross Profit | (67.78 M) | ||||
| EBITDA | (94.81 M) | ||||
| Net Income | (95.06 M) | ||||
| Cash And Equivalents | 184.76 M | ||||
| Cash Per Share | 3.81 X | ||||
| Total Debt | 1.68 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.12 X | ||||
| Book Value Per Share | 1.94 X | ||||
| Cash Flow From Operations | (79.85 M) | ||||
| Short Ratio | 4.52 X | ||||
| Earnings Per Share | (1.18) X | ||||
| Target Price | 17.67 | ||||
| Number Of Employees | 59 | ||||
| Beta | 0.03 | ||||
| Market Capitalization | 701.3 M | ||||
| Total Asset | 139.31 M | ||||
| Retained Earnings | (561.39 M) | ||||
| Working Capital | 126.79 M | ||||
| Current Asset | 13.9 M | ||||
| Current Liabilities | 10.49 M | ||||
| Year To Date Return | 1.67 % | ||||
| One Year Return | (6.49) % | ||||
| Three Year Return | (0.57) % | ||||
| Net Asset | 139.31 M | ||||
| Equity Positions Weight | 21.57 % | ||||
| Bond Positions Weight | 15.26 % |
About Altimmune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.